New Asthma Drug Needs Just 2 Shots Per Year

People with severe asthma just got a life-changing new option that could free them from monthly medication routines for good.

The European Commission has approved Exdensur, a groundbreaking asthma treatment that works with just two injections per year. The approval adds 3 million potential patients who can now access this convenient alternative to existing therapies that require monthly dosing.

Exdensur targets severe asthma in adults and teens over 12 whose symptoms persist despite high doses of corticosteroids and other medications. It also treats chronic rhinosinusitis with nasal polyps, a painful condition that causes inflammation and breathing problems.

The drug works similarly to GSK's established treatment Nucala, which generated $2.7 billion in sales last year. But Exdensur's twice-yearly dosing schedule represents a massive improvement over Nucala's monthly injections, giving patients more freedom and fewer doctor visits.

The European approval follows recent clearances in the UK, Japan, and the United States. GSK expects a regulatory decision in China later this year, potentially opening access to millions more patients worldwide.

The Ripple Effect

This approval arrives at a crucial time for the estimated 30 million Europeans living with asthma. For those with severe forms of the disease, managing symptoms often means juggling multiple daily medications, frequent medical appointments, and constant vigilance about potential triggers.

A treatment requiring just two annual visits could dramatically reduce the mental and logistical burden of managing this chronic condition. Patients could spend less time thinking about their disease and more time living their lives.

The drug also offers hope beyond asthma. Researchers are studying Exdensur for other inflammatory conditions, including chronic obstructive pulmonary disease, which affects millions more people globally.

For patients who've struggled to control their symptoms despite trying multiple treatments, this new option represents genuine progress. Dr. Kaivan Khavandi, who leads respiratory research at GSK, says Exdensur could "redefine care" by helping patients achieve their treatment goals with minimal disruption to daily life.

The approval demonstrates how medical innovation continues pushing toward more patient-friendly treatments that don't just work better but fit more seamlessly into people's lives.